ANTIVIRAL DRUGS ADVISORY COMMITTEE

October 3, 2001

NDA 21-356, VireadÔ (tenofovir disoproxil fumarate) Tablets, Gilead Sciences, Inc. Proposed for the treatment of human immunodeficiency virus (HIV) infection.

Briefing Information

Gilead Sciences, Inc.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Document pdf

Errata pdf

FDA Briefing Information

Briefing Document pdf   htm

Errata pdf htm